首页> 外文期刊>Brachytherapy >Second conservative treatment for ipsilateral breast cancer recurrence using high-dose rate interstitial brachytherapy: Preliminary clinical results and evaluation of patient satisfaction
【24h】

Second conservative treatment for ipsilateral breast cancer recurrence using high-dose rate interstitial brachytherapy: Preliminary clinical results and evaluation of patient satisfaction

机译:高剂量率间质近距离放射治疗对同侧乳腺癌复发的第二次保守治疗:初步临床结果和患者满意度评估

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To assess early clinical results and evaluate patient satisfaction in case of second conservative treatment (2nd CT) combining lumpectomy plus high-dose rate (HDR) interstitial brachytherapy for patients (pts) presenting with ipsilateral breast cancer recurrence (IBCR). Methods and Materials: From June 2005 to July 2009, 42 pts presenting with an IBCR underwent a second lumpectomy with intraoperative implantation of plastic tubes in the tumor bed. After performing the dose distribution analysis on the postimplant CT scan, a total dose of 34. Gy in 10 fractions over 5 consecutive days was delivered. Toxicity evaluation was based on the Common Terminology Criteria for Adverse Events v3.0 criteria. Applying a visual analogic scale (VAS) analysis, patient satisfaction regarding cosmetic result and 2nd CT possibility was performed after the end of brachytherapy. Results: Median followup was 21 months (range, 6-50 months) and median age at the time of local recurrence was 65 years (range, 30-85 years). Median delay between primary and recurrence was 11 years (range, 1-35 years). Median recurrence tumor size was 12. mm (range, 2-30. mm). Median number of plastic tubes and planes were nine (range, 5-12) and two (range, 1-3), respectively. Median clinical target volume was 68. cc (range, 31.2-146. cc). Second local control rate was 97%. Twenty-two pts (60%) developed complications. Cutaneous and subcutaneous fibrosis was the most frequent side effect. Median VAS satisfaction score regarding cosmetic result was 7 of 10 (range, 4-9), whereas median VAS satisfaction score for 2nd CT was 10 of 10 (range, 8-10). Conclusion: A 2nd CT for IBCR using high-dose rate brachytherapy seems feasible with encouraging results in terms of second local control with an acceptable toxicity. Patient satisfaction regarding the possibility of second breast preservation should be considered.
机译:目的:对于患有同侧乳腺癌复发(IBCR)的患者(pts),进行第二次保守治疗(2nd CT)联合肿块切除加高剂量率(HDR)间隙近距离放疗,以评估早期临床结果并评估患者满意度。方法和材料:自2005年6月至2009年7月,对42例行IBCR的患者进行了第二次肿块切除术,术中在肿瘤床上植入了塑料管。在植入后的CT扫描上进行剂量分布分析后,连续5天分10批提供总剂量34. Gy。毒性评估基于不良事件通用术语标准v3.0标准。应用视觉模拟量表(VAS)分析,在近距离放疗结束后,对美容结果和第二次CT可能性进行了患者满意度。结果:中位随访时间为21个月(范围6-50个月),局部复发时的中位年龄为65岁(范围30-85岁)。原发和复发之间的中位延迟时间为11年(范围为1-35年)。复发肿瘤的中位大小为12毫米(范围2-30。毫米)。塑料管和平面的中位数分别为9个(范围5-12)和2个(范围1-3)。中位临床目标量为68. cc(范围31.2-146。cc)。第二地方控制率为97%。 22%(60%)出现并发症。皮肤和皮下纤维化是最常见的副作用。关于美容结果的VAS满意度中位数为10分之7(4-9),而第二次CT的VAS满意度中位数为10之10(8-10)。结论:使用高剂量率近距离放射治疗进行IBCR的第二次CT似乎可行,在第二次局部控制和可接受的毒性方面取得令人鼓舞的结果。应考虑患者对第二次保留乳房的满意度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号